371 related articles for article (PubMed ID: 32098797)
1. Obeticholic Acid Ameliorates Valproic Acid-Induced Hepatic Steatosis and Oxidative Stress.
Gai Z; Krajnc E; Samodelov SL; Visentin M; Kullak-Ublick GA
Mol Pharmacol; 2020 May; 97(5):314-323. PubMed ID: 32098797
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
Ijssennagger N; Janssen AWF; Milona A; Ramos Pittol JM; Hollman DAA; Mokry M; Betzel B; Berends FJ; Janssen IM; van Mil SWC; Kersten S
J Hepatol; 2016 May; 64(5):1158-1166. PubMed ID: 26812075
[TBL] [Abstract][Full Text] [Related]
3. Effects of Farnesoid X Receptor Activation on Arachidonic Acid Metabolism, NF-kB Signaling, and Hepatic Inflammation.
Gai Z; Visentin M; Gui T; Zhao L; Thasler WE; Häusler S; Hartling I; Cremonesi A; Hiller C; Kullak-Ublick GA
Mol Pharmacol; 2018 Aug; 94(2):802-811. PubMed ID: 29743187
[TBL] [Abstract][Full Text] [Related]
4. Farnesoid X Receptor Activation by Obeticholic Acid Elevates Liver Low-Density Lipoprotein Receptor Expression by mRNA Stabilization and Reduces Plasma Low-Density Lipoprotein Cholesterol in Mice.
Singh AB; Dong B; Kraemer FB; Xu Y; Zhang Y; Liu J
Arterioscler Thromb Vasc Biol; 2018 Oct; 38(10):2448-2459. PubMed ID: 30354208
[TBL] [Abstract][Full Text] [Related]
5. Farnesoid X Receptor Protects against Kidney Injury in Uninephrectomized Obese Mice.
Gai Z; Gui T; Hiller C; Kullak-Ublick GA
J Biol Chem; 2016 Jan; 291(5):2397-411. PubMed ID: 26655953
[TBL] [Abstract][Full Text] [Related]
6. Obeticholic acid protects against diabetic cardiomyopathy by activation of FXR/Nrf2 signaling in db/db mice.
Wu H; Liu G; He Y; Da J; Xie B
Eur J Pharmacol; 2019 Sep; 858():172393. PubMed ID: 31085240
[TBL] [Abstract][Full Text] [Related]
7. Obeticholic acid prevents carbon tetrachloride-induced liver fibrosis through interaction between farnesoid X receptor and Smad3.
Fan YY; Ding W; Zhang C; Fu L; Xu DX; Chen X
Int Immunopharmacol; 2019 Dec; 77():105911. PubMed ID: 31671330
[TBL] [Abstract][Full Text] [Related]
8. Farnesoid X receptor agonist obeticholic acid inhibits renal inflammation and oxidative stress during lipopolysaccharide-induced acute kidney injury.
Zhu JB; Xu S; Li J; Song J; Luo B; Song YP; Zhang ZH; Chen YH; Xie DD; Yu DX; Xu DX
Eur J Pharmacol; 2018 Nov; 838():60-68. PubMed ID: 30196109
[TBL] [Abstract][Full Text] [Related]
9. Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis.
Adorini L; Rigbolt K; Feigh M; Roth J; Erickson M
PLoS One; 2024; 19(4):e0300809. PubMed ID: 38662778
[TBL] [Abstract][Full Text] [Related]
10. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats.
Cipriani S; Mencarelli A; Palladino G; Fiorucci S
J Lipid Res; 2010 Apr; 51(4):771-84. PubMed ID: 19783811
[TBL] [Abstract][Full Text] [Related]
11. Regulation of Intestinal UDP-Glucuronosyltransferase 1A1 by the Farnesoid X Receptor Agonist Obeticholic Acid Is Controlled by Constitutive Androstane Receptor through Intestinal Maturation.
Weber AA; Mennillo E; Yang X; van der Schoor LWE; Jonker JW; Chen S; Tukey RH
Drug Metab Dispos; 2021 Jan; 49(1):12-19. PubMed ID: 33154041
[TBL] [Abstract][Full Text] [Related]
12. 3β-Isoobeticholic acid efficiently activates the farnesoid X receptor (FXR) due to its epimerization to 3α-epimer by hepatic metabolism.
Stefela A; Kaspar M; Drastik M; Holas O; Hroch M; Smutny T; Skoda J; Hutníková M; Pandey AV; Micuda S; Kudova E; Pavek P
J Steroid Biochem Mol Biol; 2020 Sep; 202():105702. PubMed ID: 32505574
[TBL] [Abstract][Full Text] [Related]
13. The FXR agonist 6ECDCA reduces hepatic steatosis and oxidative stress induced by ethanol and low-protein diet in mice.
Lívero FA; Stolf AM; Dreifuss AA; Bastos-Pereira AL; Chicorski R; de Oliveira LG; de Souza CE; Fabossi IA; Rabitto IS; Gremski LH; Henneberg R; Telles JE; Oude Elferink RP; Acco A
Chem Biol Interact; 2014 Jun; 217():19-27. PubMed ID: 24713361
[TBL] [Abstract][Full Text] [Related]
14. Obeticholic acid protects mice against lipopolysaccharide-induced liver injury and inflammation.
Xiong X; Ren Y; Cui Y; Li R; Wang C; Zhang Y
Biomed Pharmacother; 2017 Dec; 96():1292-1298. PubMed ID: 29174575
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
Mudaliar S; Henry RR; Sanyal AJ; Morrow L; Marschall HU; Kipnes M; Adorini L; Sciacca CI; Clopton P; Castelloe E; Dillon P; Pruzanski M; Shapiro D
Gastroenterology; 2013 Sep; 145(3):574-82.e1. PubMed ID: 23727264
[TBL] [Abstract][Full Text] [Related]
16. Obeticholic acid differentially regulates hepatic injury and inflammation at different stages of D-galactosamine/lipopolysaccharide-evoked acute liver failure.
Ding W; Fan YY; Zhang C; Fu L; Chen X; Xu DX
Eur J Pharmacol; 2019 May; 850():150-157. PubMed ID: 30772394
[TBL] [Abstract][Full Text] [Related]
17. Farnesoid X Receptor Activation Promotes Hepatic Amino Acid Catabolism and Ammonium Clearance in Mice.
Massafra V; Milona A; Vos HR; Ramos RJJ; Gerrits J; Willemsen ECL; Ramos Pittol JM; Ijssennagger N; Houweling M; Prinsen HCMT; Verhoeven-Duif NM; Burgering BMT; van Mil SWC
Gastroenterology; 2017 May; 152(6):1462-1476.e10. PubMed ID: 28130067
[TBL] [Abstract][Full Text] [Related]
18. Obeticholic acid protects against carbon tetrachloride-induced acute liver injury and inflammation.
Zhang DG; Zhang C; Wang JX; Wang BW; Wang H; Zhang ZH; Chen YH; Lu Y; Tao L; Wang JQ; Chen X; Xu DX
Toxicol Appl Pharmacol; 2017 Jan; 314():39-47. PubMed ID: 27865854
[TBL] [Abstract][Full Text] [Related]
19. Curcumin attenuates ethanol-induced hepatic steatosis through modulating Nrf2/FXR signaling in hepatocytes.
Lu C; Zhang F; Xu W; Wu X; Lian N; Jin H; Chen Q; Chen L; Shao J; Wu L; Lu Y; Zheng S
IUBMB Life; 2015 Aug; 67(8):645-58. PubMed ID: 26305715
[TBL] [Abstract][Full Text] [Related]
20. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.
Jouihan H; Will S; Guionaud S; Boland ML; Oldham S; Ravn P; Celeste A; Trevaskis JL
Mol Metab; 2017 Nov; 6(11):1360-1370. PubMed ID: 29107284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]